Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Cara Therapeutics, Inc. | cara-ex321_242.htm |
| EX-31.2 - EX-31.2 - Cara Therapeutics, Inc. | cara-ex312_241.htm |
| EX-31.1 - EX-31.1 - Cara Therapeutics, Inc. | cara-ex311_240.htm |
| 10-K - 10-K - Cara Therapeutics, Inc. | cara-10k_20171231.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
(1) |
Registration Statement (Form S-3 No. 333-216657) of Cara Therapeutics Inc. |
|
(2) |
Registration Statement (Form S-3 No. 333-203072) of Cara Therapeutics Inc. |
|
(3) |
Registration Statement (Form S-8 No. 333-216606) of Cara Therapeutics Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics Inc. |
|
(4) |
Registration Statement (Form S-8 No. 333-210096) of Cara Therapeutics Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics Inc. |
|
(5) |
Registration Statement (Form S-8 No. 333-203057) of Cara Therapeutics Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics Inc., and |
|
(6) |
Registration Statement (Form S-8 No. 333-193905) pertaining to the 2004 Stock Incentive Plan, as amended, and 2014 Equity Incentive Plan; |
of our report dated March 15, 2018, with respect to the financial statements of Cara Therapeutics Inc., included in this Annual Report (Form 10-K) of Cara Therapeutics Inc., for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Stamford, Connecticut
March 15, 2018